I
IVIEW Therapeutics
Developing sustainable and innovative drugs to target unmet medical needs
About IVIEW Therapeutics
IVIEW Therapeutics Inc. is a clinical-stage biotechnology company, founded in late 2015, that is strategically positioned to address unmet needs within the ophthalmic therapeutics market. The company directs its resources toward developing treatments for a range of ocular diseases, including dry eye, infectious conjunctivitis, myopia, glaucoma, and presbyopia. As a clinical-stage entity, IVIEW's business model is centered on research and development, funded primarily through investments from stockholders, as it does not yet have approved products generating sales revenue. The company has successfully raised significant capital to advance its clinical programs, including an A++ financing round in January 2025.
The company was co-founded by Dr. Bo Liang and Dr. John J. Baldwin, both veterans of the pharmaceutical industry. Dr. Liang, the Chairman and CEO, is a serial entrepreneur with extensive experience in drug discovery. His previous success includes co-founding CLS Pharmaceuticals, whose lead asset was acquired by Shire for $300 million in 2015. Dr. Baldwin contributed 30 years to Merck, where he was instrumental in developing several medicines, including Trusopt for glaucoma. This deep industry experience underpins the company's strategy. Headquartered in Cranbury, New Jersey, IVIEW operates a research and development facility and also has a presence in China to support development in that market.
IVIEW's pipeline features several product candidates employing novel mechanisms and drug delivery platforms. A leading asset is IVW-1001, a TRPM8 agonist for dry eye disease, delivered via a differentiated ophthalmic eyelid wipe. This approach is designed to directly target receptors on the eyelid margin, differing from traditional eye drops. The company announced positive topline data from its Phase 1/2 trial for IVW-1001 in early 2025. Another key candidate is IVIEW-1201, a broad-spectrum antiseptic in-situ gel for acute conjunctivitis. This product uses a proprietary gel technology that allows for extended-release upon instillation in the eye. The company has completed Phase 2 trials for IVIEW-1201 and submitted a Phase 3 protocol to the FDA. The portfolio also includes a gene therapy project, IVW-2001, for glaucoma, which is expected to enter first-in-human trials.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2022 | $25M | $100M | Undisclosed | — |
| EARLY VCEquity / VC | Mar 2021 | $7M | $28M | Undisclosed | — |
Growth signals
Latest recorded traffic for IVIEW Therapeutics is 1.4K monthly website visits, up 180% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
IVIEW Therapeutics in the Cranbury Township ecosystem
The IVIEW Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Other known investors2 additional known investors
BioAdvance
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about IVIEW Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IVIEW Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









